Antonio R. Chaves | americanthinker.com
Is Gilead, the maker of Remdesivir, waging war on HCQ (hydroxychloroquine)? Attacks on the drug have been continuous ever since Dr. Didier Raoult used this quinine derivative to save the lives of COVID-19 patients last March. The first attempt to discredit HCQ was a hastily compiled Veterans’ Administration hospital system study last April. Notably, one of the study’s authors had in the past received numerous grants from Gilead, with one grant in 2018 totaling nearly a quarter of a million dollars.
After deep flaws in the V.A. study were exposed, Surgisphere came to the rescue in May with a “15,000 patient” megastudy allegedly compiled from hospitals all over the world. This strategy succeeded: following its publication in the Lancet and the NEJM, all outpatient use of HCQ was severely restricted in the U.S., Australia, and most of Europe.